Please assess the completion status of the following clinical trial:

Trial Title: Randomized, Placebo/Active Crossover Dose-ranging Study for Safety and Efficacy in Asthma Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Generally healthy, male and female adults aged 18 to 55 years at Screening.~2. Clinical diagnosis of intermittent, or mild-to-moderate persistent, asthma for at least 6 months before Screening, and having used inhaled epinephrine or β-agonist(s) for asthma control;~3. Demonstrating a baseline forced expiratory volume in 1 second (FEV1) at 50-90 percent of predicted normal at Screening;~4. Demonstrating a 12.0 percent or greater airway reversibility in FEV1 within 30 min after inhaling 2 actuations of Epinephrine CFC-MDI (440 mcg Epinephrine base) at Screening;~5. Females of child-bearing potential must be non-pregnant, non-lactating, and practicing a clinically acceptable form of birth control;~6. Demonstration of proficiency in the use of a MDI inhaler after training;~7. Having properly consented to participate in the trial.~Exclusion Criteria:~1. A smoking history of 10 or more pack-years, or having smoked within 6 months prior to Screening;~2. Upper respiratory tract infections within 2 wk, or lower respiratory tract infection within 4 wk, prior to Screening;~3. Asthma exacerbations that required emergency care or hospitalized treatment, within 4 wk prior to Screening;~4. Any current or recent respiratory conditions that, per investigator discretion, might significantly affect pharmacodynamic response to the study drugs, including cystic fibrosis, bronchiectasis, tuberculosis, emphysema, and other significant respiratory diseases besides asthma;~5. Concurrent clinically significant cardiovascular, hematological, renal, neurologic, hepatic, endocrine (including diabetes), psychiatric, neoplastic or other illnesses that in the opinion of the investigator could impact on the conduct, safety and evaluation of the study;~6. Known intolerance or hypersensitivity to any of the study MDI ingredients (i.e., Epinephrine, HFA-134a, CFC-12, CFC-114, polysorbate-80, ethanol, thymol, nitric acid and ascorbic acid);~7. Use of prohibited drugs or failure to observe the drug washout restrictions;~8. Having been on other investigational drug/device studies in the last 30 days prior to Screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- T1 - E004 90 mcg/actuation (Type: EXPERIMENTAL): T1 - E004 (epinephrine inhalation aerosol) 90 mcg/actuation - treatment by 2 actuations of E004 at 90 mcg/actuation
- T2 - E004 125 mcg/actuation (Type: EXPERIMENTAL): E004 (epinephrine inhalation aerosol), 125 mcg, 2 actuations
- T3 - 160 mcg/actuation (Type: EXPERIMENTAL): E004 (epinephrine inhalation aerosol), 160 mcg - E004 (epinephrine inhalation aerosol), 160 mcg/ actuation, 2 actuations
- T4 - 220 mcg/actuation (Type: EXPERIMENTAL): E004 (epinephrine inhalation aerosol), 220 mcg - 220 mcg/actuation, 2 actuations
- A - Active control (Type: ACTIVE_COMPARATOR): epinephrine inhalation aerosol, CFC propelled 220 mcg Epinephrine Inhalation Aerosol, CFC-MDI, 2 actuations
- P, Placebo HFA (Type: PLACEBO_COMPARATOR): E004 placebo single treatment with 2 inhalations

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility